Quantitative Systems Pharmacology (QSP)-Based Dose Selection for Minimum Anticipated Biological Effect Level (MABEL) in First-in-Human (FIH) Trials; Draft Guidance for Industry; Availability
FDA releases draft guidance on using QSP-based dose selection for MABEL in FIH trials, providing a new framework for dose selection.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 30, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Sponsors of first-in-human trials for biologics and other drugs where MABEL is relevant, including branded drug makers and biotech firms. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Comments due by August 25, 2026 (60 days after publication on June 24, 2026).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA issued a draft guidance outlining a quantitative systems pharmacology (QSP) approach for selecting the starting dose in FIH trials based on the minimum anticipated biological effect level (MABEL).
Who it affects
Sponsors of first-in-human trials for biologics and other drugs where MABEL is relevant, including branded drug makers and biotech firms.
What you must do
Review the draft guidance and consider incorporating QSP modeling into dose selection for upcoming FIH trials; submit comments by the deadline if desired.
Deadline
Comments due by August 25, 2026 (60 days after publication on June 24, 2026).
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trial